Groundbreaking Chemistry Research Recognized Through The Reaxys® PhD Competition
3rd Annual Reaxys®PhD Prize launched to award original and innovative research in organic, organometallic and inorganic chemistry
Neuchâtel, Switzerland, December 15, 2011 - Reaxys, a leading workflow solution that provides extensive information on chemical compounds, related physical and pharmacological properties, today announced the launch of the 3rd Annual Reaxys PhD Prize. The competition is for chemistry students currently studying for a PhD or having completed a PhD within the last 12 months.
The prize will be awarded to the candidates that best demonstrate excellence in methodology and approach in a peer-reviewed publication. Three prize winners will each receive a check for $2000 and will be invited to present their research at the Winners’ Symposium.
The 2012 Winners’ Symposium will be held at the American Chemical Society (ACS) Fall Meeting in Philadelphia, August 19– 23, 2012. The Symposium is sponsored by the ACS Division of Inorganic Chemistry and co-sponsored by the ACS Division of Organic Chemistry. The three winners will each present papers at the symposium alongside papers given by two members of the Reaxys Advisory Board – Professor Barry M. Trost (Stanford University) and Professor Dr Martin Jansen (Max Planck Institute, Stuttgart).
“After two successful years, the Reaxys PhD Prize is already establishing itself as the premier international prize for PhD Chemists,” said David Evans PhD, Scientific Affairs Director at Elsevier Properties SA. “Prior winners and finalists represent the best cutting edge chemistry research being performed by young chemists at some of the world’s top universities. We are excited to see how well this year’s candidates will measure up in terms of research excellence, rigor and innovation – qualities to which the whole Reaxys team is also committed to achieve.”
All entries will be reviewed by a review board of leading international chemists, chaired by the following members of the Reaxys Advisory Board:
- Professor A. G. M. Barrett - Imperial College London, UK
- Professor B. M. Trost - Stanford University, USA
- Professor H. N. C. Wong - Chinese University of Hong Kong, China
Submissions will be reviewed based upon originality, innovation, importance to the field, applicability, rigor of approach and publication quality.
All submissions must include a PhD Supervisor letter of recommendation, a CV and a representative peer-reviewed piece of published research. Entries should be submitted by February 15, 2012 here: http://prize.reaxys.com
# # #
About Elsevier Properties SA
Elsevier Properties SA is a center of excellence within Reed Elsevier for the management of intellectual property. Elsevier Properties SA owns the PharmaPendium and Reaxys databases. Trademarks including Reaxys®, PharmaPendium™ and The Lancet® are owned and protected by Elsevier Properties SA and used under license.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
Vice President of Global Relations, Elsevier
+ 1 215 239 3508